Optimistic Buy Rating for Atossa Therapeutics Driven by Strategic Focus on Z-endoxifen and Strong Financial Position

Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $7.00 price target.

Emily Bodnar has given her Buy rating due to a combination of factors surrounding Atossa Therapeutics’ strategic focus and financial positioning. The company is concentrating its efforts on the development of Z-endoxifen for metastatic breast cancer (mBC), particularly targeting ER+/HER2- patients. This focus is seen as a potentially quicker route to regulatory approval, given Z-endoxifen’s favorable tolerability profile compared to existing treatments that often have significant side effects.
Additionally, the competitive landscape in the oral SERD space presents an opportunity for Z-endoxifen to differentiate itself if it can demonstrate broad efficacy beyond ESR1 mutant patients. The company’s financial health, with $65.1 million in cash and equivalents at the end of 1Q25, is deemed sufficient to support ongoing operations and the advancement of Z-endoxifen’s clinical development. These strategic and financial considerations underpin Bodnar’s optimistic outlook on Atossa’s stock.